Daily Biotech Movers — 2026-08-28: An Existential-Event Tape — BioXcel's Chapter 11 and BioAtla's Delisting Anchor a 455-Name Risk-Off Session

Friday, August 28, 2026 was a risk-off session with a distinctly existential flavor at the top of the leaderboard. 117 names finished higher and 455 lower across 572 directional moves among 580 tracked companies — a 0.26-to-1 advancer ratio, the weakest breadth reading in recent memory — with a median move of -2.41% and a mean of -2.55%. The standard deviation of 5.74% understates how top-heavy the damage was: the three deepest decliners were not ordinary clinical or earnings misses but a Chapter 11 bankruptcy filing (BioXcel, -74.76%), a confirmed Nasdaq delisting (BioAtla, -44.75%), and a one-day give-back of the prior session’s +108% mania (Propanc, -39.46%). The broad tape was mildly red (SPY -0.23%) while healthcare split hard against small-cap biotech: XBI -3.48% and IBB -2.72% versus XLV -0.24% — a reversal of the prior three sessions, in which capital had preferred the high-beta biotech end. 104 names moved at least 5% on price, and 116 were anomaly-flagged once volume-only spikes are included.

The top-six geometry is the day’s story in miniature: the winners are fresh microcap events on heavy volume — CollPlant’s Q2 earnings report (+23.58% on 24.8x volume), Quoin’s positive interim QRX003 data plus a ~$30.8M institutional placement (+18.72% on 29.4x), and Akari’s continuation of its AKTX-101 run (+18.76%) — while the losers are the previous session’s mania extremes unwinding in the presence of real financial-existence events. Thursday’s two triple-digit winners (Celularity +138.5%, Propanc +108.4%) both reversed sharply Friday (Celularity -24.76%, Propanc -39.46%). When the two largest winners of one session become the two largest losers of the next — on a day the small-cap biotech ETF underperforms the S&P 500 by 3.25 points — the tape is telling you the momentum cycle is clearing, not rotating.

The Distribution

Measure	August 28 reading
Tracked / priced	580 / 572
Directional moves	572 (117 up, 455 down)
Up / down ratio	0.26-to-1 advancers
Mean / median	-2.55% / -2.41%
Standard deviation	5.74%
Price moves of at least 5%	104
Anomaly-flagged (incl. volume-only)	116

Breadth was aggressively negative — the 0.26-to-1 advancer ratio is the weakest of the month — and the negative move was broad-based: 19 of 24 sector categories printed negative averages. The sector table’s only green leaders were Devices - Surgical +1.17% (n=28) and Devices - Measurement +0.71% (n=4) — revenue-positive device names holding up as the speculative end sold off — while the laggards were the most exposed buckets: Drug Delivery/Formulation -5.18% (n=32), Cannabis-related -4.29%, Nanotechnology -4.83%, and a -11.85% print in the small n=3 Northern California bucket that is a single-name artifact, not a regional rotation. The XLV/XBI pair is the cleanest macro read: after three consecutive sessions of XBI outperforming XLV (the small-cap-preference rotation documented all week), Friday flipped the pair violently — XBI -3.48% against XLV -0.24%, a 3.24-point underperformance — the widest small-cap-biotech-vs-broad-healthcare gap of the window. The rotation into high-beta biotech did not fade; it broke.

The 6 Classes of Mover Signal

On August 28, four of the six top movers carry same-day or same-week disclosures (BTAI, QNRX, CLGN, BCAB); two are flagged continuation prints (AKTX, PPCB). That is a 4-of-6 clean-catalyst density — but the structure is inverted from a normal catalyst day: the clean prints on the loser side are existential (bankruptcy, delisting) rather than clinical, and the winner side is a mix of earnings, data-plus-financing, and momentum.

1. Halt-release or reverse-split-adjacent. None of the six top movers is a clean Class 1 print, but the pattern is visible one slot down the board: PFSA (Profusa, -30.90% on 0.29x volume, 5d -46.3%) continued its multi-day slide — the third reverse-split consolidation of 2026 for the name — on volume below normal, the mechanical signature of a pre-split tape repricing rather than capitulation.

2. Single-stock clinical or regulatory event. Two of the winners and the deepest loser are Class 2 prints. QNRX (Quoin Pharmaceuticals, +18.72%) is the cleanest clinical read of the day: positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with the study’s primary endpoint met at statistical significance, announced August 28 QuiverQuant — QRX003 trial update. BTAI (BioXcel, -74.76%) is a single-stock restructuring event rather than a clinical one — the August 28 Chapter 11 filing (see the losers section). And CLGN (CollPlant, +23.58%) is a same-day fundamental event — the Q2 2026 earnings release before Friday’s open, EPS -$0.23 versus -$0.24 consensus AskTheDate — CLGN earnings 8/28.

3. Buyout or strategic capital. No clean Class 3 accumulation print sits in the top six. The closest analogue is BTAI’s asset sale agreement with Teva — but that is a distressed-asset transaction inside a bankruptcy process, not strategic capital flowing into an operating company, and it is classified here as a restructuring event rather than a strategic-capital signal. The strategic-capital bucket is otherwise quiet; no top-15 winner shows the 15%+ 5d momentum plus 2x+ volume accumulation signature that defines genuine pre-deal positioning.

4. Sector rotation. The rotation signal is unambiguous and negative: XBI -3.48% versus XLV -0.24% versus SPY -0.23% — capital exited small-cap biotech broadly while broad healthcare and the S&P held near flat. The green device categories (Surgical +1.17%, Measurement +0.71%) are the only sector-level pockets of relative strength, consistent with a defensive tilt toward revenue-positive names on a risk-off day. This is the mirror image of Tuesday-Wednesday-Thursday, when XBI repeatedly outperformed XLV; Friday’s print breaks that streak with force.

5. Sell-the-news / prior-cycle continuation. Two of the six top movers land here, both flagged. PPCB (Propanc, -39.46%) is the day’s cleanest prior-cycle print: no August 28 disclosure exists — the move is a one-day give-back of Thursday’s +108.41% run on the August 27 preclinical pancreatic cancer data, on just 1.16x volume, with five-day momentum still +25.0% Propanc — August 27 preclinical data. AKTX (Akari, +18.76%) is a continuation of the AKTX-101 news cycle (the August 13 Q2 report and August 18 preclinical data) rather than a fresh Friday catalyst — flagged as prior-cycle below.

6. Stealth accumulation / distribution. The stealth list is short but informative on a liquidation day: ARTL (Artelo Biosciences, +0.26% on 4.99x), PTN (Palatin Technologies, -0.10% on 4.79x), BNR (Burning Rock Biotech, +1.90% on 4.10x), and TNON (Tenon Medical, -0.40% on 3.18x, 5d -26.8%). Four names holding price on 3-5x volume during a broad selloff is consistent with distribution being absorbed rather than accumulation starting — with TNON’s -26.8% five-day slide, the pattern leans distribution.

Top 3 Winners — What Drove Them

CLGN — CollPlant Biotechnologies — +23.58% on 24.84x volume

CollPlant closed at $0.358 on 8,981,827 shares — 24.84x its 30-day average — with five-day momentum of +14.6%, on an earnings-reporting day: Q2 2026 results were released August 28 before the open with EPS of -$0.23 versus the -$0.24 consensus estimate (a 3.12% surprise) AskTheDate — CLGN earnings calendar; CollPlant IR — financial results. The move is an earnings-day repricing of a beaten-down regenerative-medicine microcap — market cap ~$6.8M, price at the low end of a $0.26-$3.18 52-week range — amplified by a 24.8x volume spike on a thin float, the company’s first scheduled report since the $2.6M private placement announced June 30 CollPlant IR — $2.6M placement. An 8.98M-share session on a ~$6.8M-cap name is a full float-turnover event: the earnings beat was small in absolute terms, but on a stock that had lost 89% of its value from the 52-week high, any positive surprise can trigger a mechanical short-cover. Signal class: single-stock fundamental (earnings) on a micro-float — same-day catalyst, flow-amplified.

AKTX — Akari Therapeutics — +18.76% on 3.06x volume

Akari closed at $10.70 on 168,632 shares — 3.06x its 30-day average — with five-day momentum of +36.3%, extending a run built on the AKTX-101 story rather than any August 28 disclosure. The freshest company news is the August 27 announcement of participation in the Virtual Investor “Why Now” on-demand conference webcast Akari IR — conference participation; the driver of the multi-day advance is the AKTX-101 narrative from the prior two weeks: compelling new preclinical data for the TROP2-targeted ADC with its proprietary RNA-splicing-modulator payload announced August 18 Akari — AKTX-101 momentum, and the August 13 Q2 2026 report highlighting AKTX-101’s IND-enabling progress toward a mid-2027 Phase 1 start plus a strategic collaboration for the ADC payload platform Akari — Q2 2026 results. The +18.8% session on only 168K shares is a continuation of that momentum on light absolute volume — the strongest of the six top movers on a relative basis, and the only winner without a same-day catalyst. Signal class: Class 5 continuation of the AKTX-101 news cycle — prior-cycle catalyst, flagged.

QNRX — Quoin Pharmaceuticals — +18.72% on 29.44x volume

Quoin closed at $6.12 on 31,016,976 shares — 29.44x its 30-day average — with five-day momentum of +9.9% — after whipsawing from a pre-market gain of roughly +40% to a +18.72% close Stockstotrade — QNRX whipsaw. Two same-day August 28 catalysts sit under the tape: positive interim Phase 2/3 data for QRX003 in Netherton Syndrome showing the study’s primary endpoint was met with statistical significance QuiverQuant — QRX003 update, and a securities purchase agreement for ~$30.77 million in gross proceeds from healthcare-focused institutional investors (Aigh Capital, Nantahala Capital, Stonepine Capital, Sirenia Capital, Sphera Healthcare US, StemPoint Capital) Stockwatch — GlobeNewswire placement; MarketScreener — funding disclosure. The rally came on the data print while the financing funded the run — Benzinga framed it as “positive trial results and a major institutional financing” Benzinga — QNRX surges Friday. The 31M-share session on a name that traded sub-$1 a month ago is event-driven flow at mania intensity; the closing gain of +18.7% — less than half the pre-market read — shows the market digesting the dilution arithmetic in real time. Signal class: Class 2 clean same-day clinical catalyst plus financing on a heavily traded micro-float.

Top 3 Losers — What Drove Them

BTAI — BioXcel Therapeutics — -74.76% on 21.36x volume

BioXcel closed at $0.1814 on 58,562,917 shares — 21.36x its 30-day average — with five-day momentum of -77.4% — after filing for Chapter 11 bankruptcy protection on August 28 and entering an asset sale agreement with Teva as the stalking-horse bidder for IGALMI and BXCL501 assets Benzinga — Chapter 11 filing; BioXcel IR — asset sale agreement. The filing follows the August 21 Thirteenth Amendment to the Oaktree-administered credit agreement, which had required the company to secure a major financing or repayment transaction by August 28 StockTitan — BTAI 8-K financing deadline. The 58.5M-share session is a bankruptcy capitulation print: with the core commercial asset (IGALMI) and the lead pipeline program (BXCL501) now inside a stalking-horse sale process, the equity is repricing toward recovery value rather than operating value — and for a company whose market cap was ~$0.75B at its 2026 high, the sub-$0.20 close is the market’s verdict on unsecured equity recovery under the plan. Signal class: single-stock restructuring (Chapter 11) — clean same-day catalyst.

BCAB — BioAtla — -44.75% on 10.70x volume

BioAtla closed at $1.735 on 1,034,112 shares — 10.70x its 30-day average — with five-day momentum of -45.4% — as the market priced the final Nasdaq sessions ahead of delisting. The Nasdaq Listing Council affirmed the delisting decision on August 26, with suspension effective August 31 and trading shifting to OTC Markets, while a strategic review initiated in March 2026 continues TipRanks — BioAtla delisting; Panabee — delisting and strategic review; StockTitan — BCAB 8-K. The affirmation — following the February 8, 2026 appeal stay — removes the listing as a bid-floor support for the CAB antibody platform developer (mecbotamab vedotin, ozuriftamab vedotin), and Friday’s -44.75% session is the capitulation leg into Monday’s suspension, with the 8-K flagging liquidity, funding and going-concern risks. The 10.7x volume is heavy but not panicked — a strategic-review name with an OTC fallback draws a different seller base than a bankruptcy. Signal class: listing/regulatory event — same-week catalyst effective next session.

PPCB — Propanc Biopharma — -39.46% on 1.16x volume

Propanc closed at $1.35 on 4,057,033 shares — 1.16x its 30-day average — with five-day momentum of +25.0% — a one-day give-back of Thursday’s mania: after the stock doubled (+108.41%) on August 27 following the preclinical pancreatic cancer data release (PRP showing >90% tumor growth inhibition and a >2.5-fold survival benefit) Propanc — preclinical data, Friday’s -39.46% session on near-normal volume is profit-taking and flow exhaustion, not a fresh negative catalyst — no August 28 disclosure exists. The name had been in a classic micro-float news cycle all month (a spike to a $1.60 high on August 6, range-bound trade, then Thursday’s doubling Stockstotrade — PPCB chart), and Friday’s print unwinds a portion of that move on 1.16x volume — a low-float give-back rather than capitulation, with the five-day momentum still green at +25.0%. Signal class: Class 5 sell-the-news / prior-cycle give-back — flagged.

The Cross-Cutting Pattern

The day’s defining feature: an existential-event loser board on a broad risk-off tape — the three deepest decliners are a Chapter 11 filing, a confirmed Nasdaq delisting, and a mania give-back, while the three winners are fresh microcap events on heavy volume. BioXcel’s bankruptcy, BioAtla’s delisting, and Propanc’s give-back are three different flavors of the same force — the market stripping value from names whose next chapter is financial-existence risk — while CollPlant’s earnings beat, Quoin’s data-plus-financing print, and Akari’s momentum continuation are the event-driven flow that survived the selloff. The asymmetry is the story: the winner board’s top print (+23.58%) is a fraction of the loser board’s top print (-74.76%), and the advancer ratio of 0.26-to-1 is the weakest of the month — this is not a rotation day, it is a clearing day.

The secondary thread is the violent reversal of the prior session’s momentum extremes. Thursday’s two triple-digit winners — Celularity (+138.53%) and Propanc (+108.41%) — both collapsed Friday (Celularity -24.76%, Propanc -39.46%), with Celularity falling from the #1 winner slot to the #5 loser slot in a single session on 1.90x volume. When the tape’s two biggest momentum stories reverse the very next day on a risk-off tape, the microcap mania cycle of the past week (Celularity’s MuseCell collaboration, Propanc’s preclinical read) is in unwind — and the unwind is happening into a session where institutional capital is exiting small-cap biotech broadly.

The third thread is the XLV/XBI pair breaking. After three consecutive sessions of XBI outperforming XLV — the small-cap-preference rotation documented throughout this week — Friday printed XBI -3.48% against XLV -0.24%, a 3.24-point underperformance that is the widest of the window. The capital that had been concentrating within healthcare toward high-beta biotech reversed direction in a single session, and the only green sector categories (Devices - Surgical +1.17%, Devices - Measurement +0.71%) are the defensive, revenue-positive end. The week’s rotation thesis — small-cap biotech as the favored risk expression inside healthcare — broke on the first day the leaderboard was dominated by bankruptcy and delisting risk rather than clinical catalysts.

The 5 Data Points That Matter

1. % change vs sector mean. The winners stood far above a -2.55% day mean: CLGN +23.58% against a Medical Specialties-type microcap base, AKTX +18.76%, QNRX +18.72% against the broader oncology/specialty bucket. The losers sat 37-72 points below the mean — BTAI -74.76%, BCAB -44.75%, PPCB -39.46% — a loser gap so large it defines the day: the mean itself was dragged negative by the existential prints rather than by broad drift. The spread between the #1 winner (+23.58%) and the #1 loser (-74.76%) is 98 points — the widest winner/loser spread of the month.

2. Volume ratio. The three winners and two of the three losers are among the heaviest volume-anomaly prints on the board: QNRX 29.44x, CLGN 24.84x, BTAI 21.36x, BCAB 10.70x, AKTX 3.06x — all event prints. The outlier is PPCB at 1.16x: the give-back happened on below-average conviction volume, which is the signature of a low-float unwind rather than capitulation — sellers took liquidity where it was offered without panic. The 58.5M shares in BTAI and 31M in QNRX are extraordinary for names that size.

3. 5-day momentum. The winners are a mix of fresh and continuation: CLGN +14.6% (a turn after a long slide), QNRX +9.9% (data-day acceleration), AKTX +36.3% (a multi-week run). The losers split between accelerating-into-event and still-green: BTAI -77.4% and BCAB -45.4% are multi-session collapses into Friday’s disclosures, while PPCB is still +25.0% for the week — the mania has unwound only part of its gains.

4. 52-week range. Every top-six name trades in the lower half of its band: BTAI at $0.1814 is a sub-$0.20 bankruptcy price; CLGN at $0.358 sits against a $3.18 high (89% off); BCAB at $1.735, PPCB at $1.35, QNRX at $6.12 and AKTX at $10.70 are all far from year highs. There is no fresh-52-week-high story anywhere in the top six — the outsized percentages are repricings of low bases and low floats, not breakouts.

5. Cash / dilution context. The financial-existence layer is the quiet driver on the loser side: BTAI’s Chapter 11 is the endpoint of the Oaktree financing-deadline treadmill (Thirteenth Amendment, August 21, requiring a deal by August 28), and BCAB’s delisting 8-K explicitly flags liquidity and going-concern risk. On the winner side, QNRX’s ~$30.77M placement at institutional terms funds the QRX003 program but adds supply that the tape was already pricing intraday (the pre-market +40% faded to +18.7%). CLGN’s earnings came two months after a $2.6M placement — the fundamental event of record, but on a balance sheet that still requires external capital. The 5-point summary: respect QNRX’s data-and-financing print and CLGN’s earnings repricing as real same-day events, treat AKTX as prior-cycle momentum, and recognize BTAI, BCAB, and PPCB as the financial-existence end of the leaderboard — a day whose downside was existential and whose upside was microcap event flow.

What This Synthesis Will and Won’t Tell You

This is a one-day reading, and it should be read as such. It tells you what moved and why — the 116 anomaly-flagged names, the six data-defined top movers, the class of signal behind each, and the cross-cutting pattern: an existential-event tape (117 up / 455 down, median -2.41%) in which the losers were Chapter 11 (BTAI), a confirmed delisting (BCAB), and a mania give-back (PPCB), while the winners were earnings (CLGN), data-plus-financing (QNRX), and momentum (AKTX), all on a session where XBI -3.48% underperformed SPY -0.23% by 3.25 points. It does not tell you what happens next: whether BTAI’s equity retains any recovery value under the Teva stalking-horse process (in Chapter 11, common equity is frequently worth little — Friday’s print may not be the final repricing); whether BCAB finds a bid on OTC Markets Monday after the August 31 suspension, or whether the March 2026 strategic review produces a transaction; whether QNRX’s financing-day rally resolves into accumulation or dilution-driven fade; whether CLGN’s tiny EPS beat holds any follow-through; or whether PPCB’s give-back stops at -39% or extends toward the pre-mania base.

The honest limits: the why-investigation covers the six data-defined top movers only — mid-board prints elsewhere (AEMD +14.75% on 21.45x, FEMY +14.70%, DWTX +14.22%; PFSA -30.90%, CELU -24.76%, XAIR -21.40%, KZIA -19.64%) carry their own stories that are noted but not deep-dived. Two of the six top movers are flagged for no fresh same-day catalyst — AKTX (continuation of the AKTX-101 cycle) and PPCB (give-back of Thursday’s data-driven mania) — a deliberate refusal to invent Friday headlines for momentum prints; the synthesis keeps them in the leaderboard because they are the data-defined movers. And a single session says nothing about the week or the quarter — but the durable signal is already visible across sessions: the microcap mania cycle that produced triple-digit winners on August 27 reversed violently on August 28 (PPCB, CELU), the small-cap-over-defensive rotation inside healthcare broke in a single session (XBI under XLV by 3.24 points), and the financial-existence complex (Chapter 11, delisting, cash-runway risk) has re-emerged as the dominant driver of the deepest daily moves.

---

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-08-28 and will change with market conditions, clinical readouts, financing terms, bankruptcy proceedings, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Sources: Benzinga — BioXcel Chapter 11 filing and Teva stalking-horse bid; BioXcel IR — asset sale agreement with Teva; StockTitan — BTAI 8-K financing deadline; TipRanks — BioAtla delisting decision; Panabee — BioAtla delisting and strategic review; StockTitan — BCAB 8-K suspension; Propanc — PRP preclinical pancreatic data; AskTheDate — CLGN earnings calendar 8/28; CollPlant IR — financial results; CollPlant IR — $2.6M placement; Akari IR — conference participation; Akari — AKTX-101 momentum; Akari — Q2 2026 results; QuiverQuant — QRX003 trial update; Stockwatch — QNRX private placement; Benzinga — QNRX surges Friday; Stockstotrade — QNRX whipsaw; Stockstotrade — PPCB chart; MarketScreener — QNRX funding disclosure.